Shane Schaffer is the visionary Co-founder, Chairman, and CEO of Cingulate Therapeutics, headquartered in Kansas City, Kansas. This Phase 3 clinical-stage biopharmaceutical company is renowned for its innovative approach to developing next-generation pharmaceuticals, notably focusing on Attention Deficit/Hyperactivity Disorder (ADHD), anxiety disorders, and insomnia. Boasting a 25-year tenure in the pharmaceutical industry, Dr. Schaffer is an acclaimed drug development and commercialization expert. His leadership has been instrumental across various facets of business operations, such as product launches, brand planning, joint venture brand management, life cycle management, and market development, securing his reputation in the biopharmaceutical and marketing arenas. He earned his doctoral degree in Pharmacy from the University of Kansas in 1999, followed by a postdoctoral pharmaceutical industry fellowship at Rutgers University's College of Pharmacy. His professional journey included impactful stints at Pfizer Worldwide Marketing and Morris Plains, where he honed his strategic marketing and research management skills. While at Pfizer Worldwide Marketing in New York, he assumed the role of Marketing Manager, skillfully developing pre-launch strategies and launching the Global Communications Intranet to streamline communications between medical and marketing stakeholders. He also aided in crafting and executing the Pfizer Medical and Academic Partnership in Pain Management. In New Jersey, he excelled as a Project Manager and External Research Manager at Morris Plains. He oversaw advanced sales training and managed Phase IV Medical Research for all marketed brands, showcasing his comprehensive management capabilities. His career progression saw him assuming pivotal roles at Pfizer, Novartis, and Sanofi, where he spearheaded the commercialization of several billion-dollar brands. At Novartis, as a Product Manager, he successfully led the launches of Ritalin® LA and Focalin™, achieving remarkable market penetration and rapid brand awareness, meriting multiple industry accolades. Continuing his trajectory at Sanofi, he was instrumental during the company's mergers and joint ventures, notably enhancing the market presence of Avapro and Avalide through strategic promotions and effective salesforce execution. In 2008, he transitioned to a consultancy role at M|C Communications LLC in Boston, leading the development of business opportunities for major pharmaceutical firms. He founded Sabre Scientific Solutions, LLC in 2009, where he provided expert consulting services in commercials, clinical strategies, product launches, and leadership. Driven by a passion for addressing ADHD, he founded Cingulate Therapeutics LLC in January 2013, focusing on cutting-edge drug delivery technologies for ADHD and anxiety disorders. The company has since partnered with Indegene to market its phase-3 oral ADHD medication, CTx-1301, and is poised to submit a new drug application to the FDA by mid-2025. Beyond his corporate achievements, Shane Schaffer is deeply committed to philanthropy. He actively supports the Folds of Honor Charity, which provides educational scholarships to children of fallen or disabled military personnel. His dedication extends beyond professional success, impacting community welfare and supporting future generations.